{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:58:46Z","timestamp":1785466726246,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40123-026-01436-8","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:43:59Z","timestamp":1782179039000},"page":"2607-2625","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravitreal Faricimab for Retinal Vein Occlusion: Real-World Outcomes from the Multicenter FARTURK-RVO Study in T\u00fcrkiye"],"prefix":"10.1007","volume":"15","author":[{"given":"Fevzi","family":"Akkan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1812-7600","authenticated-orcid":false,"given":"Ebru","family":"G\u00f6rg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0650-4552","authenticated-orcid":false,"given":"Burak","family":"Erden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1735-2670","authenticated-orcid":false,"given":"Yavuz Kamil","family":"Bardak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6818-9240","authenticated-orcid":false,"given":"Nigar","family":"\u015eerif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9440-4000","authenticated-orcid":false,"given":"Mahmut","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0834-1822","authenticated-orcid":false,"given":"Erkan","family":"\u00c7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9957-0673","authenticated-orcid":false,"given":"Selim","family":"B\u00f6l\u00fckba\u015f\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4651-8177","authenticated-orcid":false,"given":"\u015eefik Can","family":"\u0130pek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6931-4970","authenticated-orcid":false,"given":"Tahsin","family":"Uzundede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4125-4819","authenticated-orcid":false,"given":"Gamze","family":"Karata\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9604-6887","authenticated-orcid":false,"given":"Murat","family":"Karapapak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-9308","authenticated-orcid":false,"given":"Ece","family":"\u00d6zal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4677-8398","authenticated-orcid":false,"given":"Osman Murat","family":"Uyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-3160","authenticated-orcid":false,"given":"Do\u011fukan","family":"C\u00f6merter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7357-5399","authenticated-orcid":false,"given":"Mehmet Numan","family":"Alp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3392-3090","authenticated-orcid":false,"given":"Serhat","family":"Ermi\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9173-854X","authenticated-orcid":false,"given":"An\u0131l","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7832-5831","authenticated-orcid":false,"given":"Murat","family":"Ar\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7346-164X","authenticated-orcid":false,"given":"Mehmet Egemen","family":"Karata\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9940-8599","authenticated-orcid":false,"given":"Nursal Melda","family":"Yenerel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2002-7393","authenticated-orcid":false,"given":"Halil \u00d6zg\u00fcr","family":"Artunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-6716","authenticated-orcid":false,"given":"Ecem","family":"\u00d6nder-Toku\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7860-4603","authenticated-orcid":false,"given":"Veysel Levent","family":"Karaba\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4670-1677","authenticated-orcid":false,"given":"Melih","family":"\u00dcnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9723-859X","authenticated-orcid":false,"given":"Ziya","family":"Kapran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-4265","authenticated-orcid":false,"given":"Hakan","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-283X","authenticated-orcid":false,"given":"Ak\u0131n","family":"\u00c7ak\u0131r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"3","key":"1436_CR1","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/IAE.0000000000000843","volume":"36","author":"M Ho","year":"2016","unstructured":"Ho M, Liu DTL, Lam DSC, Jonas JB. Retinal vein occlusions, from basics to the latest treatment. Retina. 2016;36(3):432\u201348. https:\/\/doi.org\/10.1097\/IAE.0000000000000843.","journal-title":"Retina"},{"issue":"4","key":"1436_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/ceo.14225","volume":"51","author":"EE Cornish","year":"2023","unstructured":"Cornish EE, Zagora SL, Spooner K, Fraser-Bell S. Management of macular oedema due to retinal vein occlusion: an evidence-based systematic review and meta-analysis. Clin Exp Ophthalmol. 2023;51(4):313\u201338. https:\/\/doi.org\/10.1111\/ceo.14225.","journal-title":"Clin Exp Ophthalmol"},{"issue":"13","key":"1436_CR3","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.3390\/jcm13133950","volume":"13","author":"M Lendzioszek","year":"2024","unstructured":"Lendzioszek M, Bryl A, Poppe E, Zorena K, Mrugacz M. Retinal vein occlusion-background knowledge and foreground knowledge prospects-A review. J Clin Med. 2024;13(13):3950. https:\/\/doi.org\/10.3390\/jcm13133950.","journal-title":"J Clin Med"},{"key":"1436_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40942-020-00250-z","volume":"6","author":"QD Nguyen","year":"2020","unstructured":"Nguyen QD, Heier JS, Do DV, et\u00a0al. The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. Int J Retina Vitreous. 2020;6:48. https:\/\/doi.org\/10.1186\/s40942-020-00250-z.","journal-title":"Int J Retina Vitreous"},{"issue":"5","key":"1436_CR5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","volume":"263","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Mar F, Amador MJ, et\u00a0al. Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases. Graefes Arch Clin Exp Ophthalmol. 2025;263(5):1239\u201347. https:\/\/doi.org\/10.1007\/s00417-024-06695-4.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"1436_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000502041","volume":"242","author":"U Schmidt-Erfurth","year":"2019","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et\u00a0al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242(3):123\u201362. https:\/\/doi.org\/10.1159\/000502041.","journal-title":"Ophthalmologica"},{"issue":"11","key":"1436_CR7","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1007\/s00417-024-06531-9","volume":"262","author":"H Agostini","year":"2024","unstructured":"Agostini H, Abreu F, Baumal CR, et\u00a0al. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. Graefes Arch Clin Exp Ophthalmol. 2024;262(11):3437\u201351. https:\/\/doi.org\/10.1007\/s00417-024-06531-9.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"1436_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13643-023-02261-x","volume":"12","author":"H Shahzad","year":"2023","unstructured":"Shahzad H, Mahmood S, McGee S, et\u00a0al. Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. Syst Rev. 2023;12(1):92. https:\/\/doi.org\/10.1186\/s13643-023-02261-x.","journal-title":"Syst Rev"},{"issue":"8","key":"1436_CR9","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, et\u00a0al. Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials. Ophthalmology. 2024;131(8):950\u201360. https:\/\/doi.org\/10.1016\/j.ophtha.2024.01.029.","journal-title":"Ophthalmology"},{"key":"1436_CR10","doi-asserted-by":"publisher","first-page":"1646806","DOI":"10.3389\/fphar.2025.1646806","volume":"16","author":"Y Jing","year":"2025","unstructured":"Jing Y, Li D. Faricimab for retinal vein occlusion: a review of current evidence and future perspectives. Front Pharmacol. 2025;16:1646806. https:\/\/doi.org\/10.3389\/fphar.2025.1646806.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1436_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40942-025-00703-3","volume":"11","author":"T Hirakata","year":"2025","unstructured":"Hirakata T, Toride A, Ashikaga K, et\u00a0al. Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion. Int J Retina Vitreous. 2025;11(1):79. https:\/\/doi.org\/10.1186\/s40942-025-00703-3.","journal-title":"Int J Retina Vitreous"},{"issue":"7","key":"1436_CR12","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.3390\/jcm14072454","volume":"14","author":"M Hafner","year":"2025","unstructured":"Hafner M, Herold TR, Kufner A, et\u00a0al. Switching to faricimab in therapy-resistant macular edema due to retinal vein occlusion: initial real-world efficacy outcomes. J Clin Med. 2025;14(7):2454. https:\/\/doi.org\/10.3390\/jcm14072454.","journal-title":"J Clin Med"},{"issue":"2","key":"1436_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","volume":"105","author":"TA Ciulla","year":"2021","unstructured":"Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes. Br J Ophthalmol. 2021;105(2):216\u201321. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-315933.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"1436_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40123-023-00672-6","volume":"12","author":"OA Sam-Oyerinde","year":"2023","unstructured":"Sam-Oyerinde OA, Patel PJ. Real-world outcomes of anti-VEGF therapy in diabetic macular oedema: barriers to treatment success and implications for low\/lower-middle-income countries. Ophthalmol Ther. 2023;12(2):809\u201326. https:\/\/doi.org\/10.1007\/s40123-023-00672-6.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1436_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/biomedicines13010105","volume":"13","author":"DM Darabu\u015f","year":"2025","unstructured":"Darabu\u015f DM, D\u0103r\u0103bu\u015f RG, Munteanu M. The diagnosis and treatment of branch retinal vein occlusions: an update. Biomedicines. 2025;13(1):105. https:\/\/doi.org\/10.3390\/biomedicines13010105.","journal-title":"Biomedicines"},{"issue":"9","key":"1436_CR16","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.oret.2025.03.005","volume":"9","author":"CJ Danzig","year":"2025","unstructured":"Danzig CJ, Dinah C, Ghanchi F, et\u00a0al. Faricimab treat-and-extend dosing for macular edema due to retinal vein occlusion: 72-week results from the BALATON and COMINO trials. Ophthalmol Retina. 2025;9(9):848\u201359. https:\/\/doi.org\/10.1016\/j.oret.2025.03.005.","journal-title":"Ophthalmol Retina"},{"key":"1436_CR17","doi-asserted-by":"publisher","first-page":"1192464","DOI":"10.3389\/fncel.2023.1192464","volume":"17","author":"J Canonica","year":"2023","unstructured":"Canonica J, Foxton R, Garcia Garrido M, et\u00a0al. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion. Front Cell Neurosci. 2023;17:1192464. https:\/\/doi.org\/10.3389\/fncel.2023.1192464.","journal-title":"Front Cell Neurosci"},{"issue":"11","key":"1436_CR18","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, et\u00a0al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265\u201388. https:\/\/doi.org\/10.15252\/emmm.201505889.","journal-title":"EMBO Mol Med."},{"issue":"1","key":"1436_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40942-024-00525-9","volume":"10","author":"FM Penha","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, et\u00a0al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in nAMD and DME. Int J Retina Vitreous. 2024;10(1):5. https:\/\/doi.org\/10.1186\/s40942-024-00525-9.","journal-title":"Int J Retina Vitreous"},{"issue":"10326","key":"1436_CR20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et\u00a0al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","journal-title":"Lancet"},{"issue":"1","key":"1436_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40360-025-00902-6","volume":"26","author":"C Liu","year":"2025","unstructured":"Liu C, Li S, Wang Z, Li Z, et\u00a0al. Safety profile of faricimab: a multi-source pharmacovigilance analysis using FAERS and JADER. BMC Pharmacol Toxicol. 2025;26(1):82. https:\/\/doi.org\/10.1186\/s40360-025-00902-6.","journal-title":"BMC Pharmacol Toxicol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01436-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01436-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01436-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:04:38Z","timestamp":1785463478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01436-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1436"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01436-8","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Fevzi Akkan, Ebru G\u00f6rg\u00fcn, Burak Erden, Yavuz K\u00e2mil Bardak, Nig\u00e2r \u015eerif, Mahmut \u00d6zt\u00fcrk, Erkan \u00c7elik, Selim B\u00f6l\u00fckba\u015f\u0131, \u015eefik Can \u0130pek, Tahsin Uzundede, Gamze Karata\u015f, Murat Karapapak, Ece \u00d6zal, Osman Murat Uyar, Do\u011fukan C\u00f6merter, Mehmet Numan Alp, Serhat Ermi\u015f, An\u0131l Korkmaz, Murat Ar\u0131c\u0131, Mehmet Egemen Karata\u015f, Nursal Melda Yenerel, Halil \u00d6zg\u00fcr Artunay, Ecem \u00d6nder Toku\u00e7, Veysel Levent Karaba\u015f, Melih \u00dcnal, Ziya Kapran, Hakan \u00d6zdemir and Ak\u0131n \u00c7ak\u0131r declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and its later amendments. Ethical approval was granted by the Istanbul Medipol University Ethics Committee (approval ID: E-10840098-50.04-2136). Written informed consent for intravitreal treatment and the secondary use of anonymized clinical data was obtained from all participants prior to inclusion.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}